MedPath

Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trial

Conditions
rectal cancer
rectal carcinoma
10017990
10017991
10017998
Registration Number
NL-OMON51912
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
45
Inclusion Criteria

primary intermediate risk rectal adenocarcinoma, fit for multimodal treatment

Exclusion Criteria

contra-indication for magnetic resonance-guided treatment or for pelvic
radiotherapy (such as inflammatory bowel disease, prior pelvic radiotherapy,
pregnancy, hip implants)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath